Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of disitamab vedotin in HER2-expressing advanced rare malignant tumors after standard therapy failure
ChiCTR2400083796Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2400083796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083796.